Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary J Zimmermann

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Pharmacological and Toxicological Methods|May 9, 2021
Study design criteria for regulatory-based drug control action: Drug discriminationDavid V Gauvin, Zachary J Zimmermann
Psychopharmacology|November 12, 2018
A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdueDavid V Gauvin, Zachary J Zimmermann
Journal of Pharmacological and Toxicological Methods|March 20, 2019
FOB vs modified Irwin: What are we doing?David V Gauvin, Zachary J Zimmermann
The Behavior Analyst|September 9, 2016
JEAB Research Over Time: Species Used, Experimental Designs, Statistical Analyses, and Sex of SubjectsZachary J Zimmermann, Erin E Watkins, Alan Poling
Journal of Psychopharmacology (Oxford, England)|June 20, 2018
Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley ratsZachary J Zimmermann, David V Gauvin, Alan Poling
Drug and Alcohol Dependence|September 16, 2016
Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?David V Gauvin, Zachary J Zimmermann, Mary Jeanne Kallman
Journal of Pharmacological and Toxicological Methods|February 25, 2019
Establishing performance characteristics for positive control article selection in drug self-administration studiesDavid V Gauvin, Zachary J Zimmermann, Mary Jeanne Kallman
Regulatory Toxicology and Pharmacology : RTP|November 23, 2018
In further defense of nonclinical abuse liability testing of biologicsDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Journal of Pharmacological and Toxicological Methods|March 20, 2017
Method of data interpretation for the determination of abuse liability in rodent self-administration studies under the FDA guidance documentDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Regulatory Toxicology and Pharmacology : RTP|January 12, 2022
De-risking in Tier I CNS safety assessments is the primary function of study design and technical training of laboratory staff observersDavid V Gauvin, Zachary J Zimmermann, Jill A Dalton
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Pharmacological and Toxicological Methods|May 9, 2021
Study design criteria for regulatory-based drug control action: Drug discriminationDavid V Gauvin, Zachary J Zimmermann
Psychopharmacology|November 12, 2018
A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdueDavid V Gauvin, Zachary J Zimmermann
Journal of Pharmacological and Toxicological Methods|March 20, 2019
FOB vs modified Irwin: What are we doing?David V Gauvin, Zachary J Zimmermann
The Behavior Analyst|September 9, 2016
JEAB Research Over Time: Species Used, Experimental Designs, Statistical Analyses, and Sex of SubjectsZachary J Zimmermann, Erin E Watkins, Alan Poling
Journal of Psychopharmacology (Oxford, England)|June 20, 2018
Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley ratsZachary J Zimmermann, David V Gauvin, Alan Poling
Drug and Alcohol Dependence|September 16, 2016
Current FDA regulatory guidance on the conduct of drug discrimination studies for NDA review: Does the scientific literature support recent recommendations?David V Gauvin, Zachary J Zimmermann, Mary Jeanne Kallman
Journal of Pharmacological and Toxicological Methods|February 25, 2019
Establishing performance characteristics for positive control article selection in drug self-administration studiesDavid V Gauvin, Zachary J Zimmermann, Mary Jeanne Kallman
Regulatory Toxicology and Pharmacology : RTP|November 23, 2018
In further defense of nonclinical abuse liability testing of biologicsDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Journal of Pharmacological and Toxicological Methods|March 20, 2017
Method of data interpretation for the determination of abuse liability in rodent self-administration studies under the FDA guidance documentDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Regulatory Toxicology and Pharmacology : RTP|January 12, 2022
De-risking in Tier I CNS safety assessments is the primary function of study design and technical training of laboratory staff observersDavid V Gauvin, Zachary J Zimmermann, Jill A Dalton
Pageof 3